期刊
ATHEROSCLEROSIS
卷 277, 期 -, 页码 256-261出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2018.06.009
关键词
Familial hypercholestesterolemia; Low density lipoprotein cholesterol; Gene analysis; FH prevalence; Argentina
资金
- Amgen Biotechnology Company, Thousand Oaks, CA, USA
- University of Buenos Aires, Argentina [20020170100259BA]
- Roemmers Foundation Argentina
- Boston Heart Diagnostics, Framingham, MA USA
Background and aims: Marked hypercholesterolemia, defined as low density lipoprotein cholesterol (LDL-C) levels >= 190 mg/dL, may be due to LDLR, APOB, and PCSK9 variants. In a recent analysis, only 1.7% of cases had such variants. Our goal was to identify other potential genetic causes of hypercholesterolemia. Methods: In a total of 51,253 subjects with lipid testing, 3.8% had elevated total cholesterol >300mg/dL and/or LDL-C >= 190 mg/dL. Of these, 246 were further studied, and 69 without kidney, liver, or thyroid disease and who met Dutch Lipid Clinic Network criteria of >= 6 points had DNA sequencing done at the LDLR, APOB, PCSK9, APOE, LDLRAP1, STAP1, ABCG5, ABCG8, CYP27A1, LIPA, LIPC, LIPG, LPL, and SCARB1 gene loci and also had 10 SNP analysis for a weighted high LDL-C genetic risk score. Results: In the 69 subjects with genetic analyses, the following variants were observed in 37 subjects (53.6%): LDLR (n = 20, 2 novel), ABCG5/8 (n = 7, 2 novel), APOB (n = 3, 1 novel), CYP27A1 (n = 3, 1 novel), LIPA (n = 2, 1 novel), APOE (n = 2), LIPC (n = 1, novel), LIPG (n = 1, novel), and SCARB1 (n = 1); 14 subjects (20.3%) had a high polygenic score, with 4 (5.8%) having no variants. Conclusions: Our data indicate that in addition to variants in LDLR, APOB, PCSK9, APOE, LDLRAP1, and STAP1, variants in ABCG5/8, CYP27A1, LIPA, LIPC, and LIPG may be associated with hypercholesterolemia and such information should be used to optimize therapy. (c) 2018 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据